Tambotatug pelitecan clinical trials
Also written YL201.
How each study uses tambotatug pelitecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tambotatug pelitecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 1
MediLink Therapeutics (Suzhou) Co., Ltd. (12) · Amgen (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)
Often tested with
Tested in the same studies.
AMG 757 (1) · Izalontamab brengitecan (1) · CVL006 (1) · KXV01 (1) · MT027 (1) · QH101 (1) · META10 (1) · TAEST1901 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test tambotatug pelitecan.
- Jan 2027A Study of YL201 and Ivonescimab (AK112) in Advanced Solid TumorsPhase 1/2 · MediLink Therapeutics (Suzhou) Co., Ltd.
- Feb 2027A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPCPhase 2 · MediLink Therapeutics (Suzhou) Co., Ltd.
- Apr 2027A Study of YL201 in Patients With Advanced Solid TumorsPhase 1/2 · MediLink Therapeutics (Suzhou) Co., Ltd.
- Apr 2027A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid TumorsPhase 1 · MediLink Therapeutics (Suzhou) Co., Ltd.
Studies
Open first, then newest update. How each study uses tambotatug pelitecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid TumorsRecruitingPhase 1/2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07407933Written as YL201
- A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic ChemotherapyNot yet recruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07803783Written as Tambotatug pelitecan
- A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07739758Written as YL201
- A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line TherapyRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07487896Written as YL201
- A Study of YL201 in Patients With Advanced Solid TumorsRecruitingPhase 1/2MediLink Therapeutics (Suzhou) Co., Ltd.NCT05434234Written as YL201
- A Study of YL201 and Ivonescimab (AK112) in Advanced Solid TumorsRecruitingPhase 1/2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07208773Written as YL201
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07307053Written as YL-201
- A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingPhase 1/2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07258979Written as YL201
- A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPCRecruitingPhase 2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06241846Written as YL201 for Injection
- A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)Active, not recruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT06629597Written as YL201
- A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)Active, not recruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT06612151Written as YL201
- A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid TumorsActive, not recruitingPhase 1MediLink Therapeutics (Suzhou) Co., Ltd.NCT06394414Written as YL201
- Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)Active, not recruitingPhase 1AmgenNCT06898957Written as YL201
- A Study YL201 in Patients With Selected Advanced Solid TumorsActive, not recruitingPhase 1/2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06057922Written as YL201 for Injection
Codes
What other systems call tambotatug pelitecan · ClinicalTrials.gg INT015208
- UNII (FDA) 66NNR5T69QTAMBOTATUG PELITECANOne source FDA
- NCI Thesaurus C188794Tambotatug PelitecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 66NNR5T69Q | TAMBOTATUG PELITECAN | One source FDA |
| NCI Thesaurus | C188794 | Tambotatug Pelitecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.